A Cosmeceutical Formulation Based On Boswellic ...

Use Of Tazarotene Foam For The Treatment Of Acn...

Ustekinumab For The Treatment Of Psoriatic Arth...

A Randomized, Double-blind, Placebo-controlled ...

Emerging Permanent Filler Technologies: Focus O...

0 votes
Ustekinumab For The Treatment Of Psoriatic Arthritis: An Update
Author: Parastoo Davari, Michael S Leo, Faranak Kamangar, Nasim Fazel
Publisher: Derivative Works
7 pages
One time payment: €0.00
Required subscription: Free
Type of publication: Article
ISBN/ISSN: 1178-7015
DOI: 10.2147/CCID.S50003
Follow this publisher

Share this publication:


Abstract: Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a fully human monoclonal antibody, for the management of psoriatic arthritis. In this article, we review large-scale randomized clinical trials addressing the efficacy and safety profile of ustekinumab for the treatment of psoriatic arthritis.

About the publisher:

We are a publishing house devoted to reuse CC-BY licensed published materials.


Using CC-BY licenses:


  • Adapt — remix, transform, and build upon the material
  • for any purpose, even commercially.
  • The licensor cannot revoke these freedoms as long as you follow the license terms.


  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others
    from doing anything the license permits.


  • You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
  • No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.

Select a payment method